Sections
Title | Starting Page | Number of Pages |
---|
1 Table of Contents | 2 | 3 |
1.1 List of Tables | 3 | 1 |
1.2 List of Figures | 3 | 2 |
2 Executive Summary | 5 | 1 |
2.1 Significant Unmet Needs in Diabetic Complications Market | 5 | 1 |
2.2 High Proportion of First-in-Class Innovation Offers Promise in Diabetic Complications | 5 | 1 |
2.3 Deal Activity Varies with First-in-Class Status | 5 | 1 |
3 The Case for Innovation | 6 | 4 |
3.1 Growing Opportunities for Biologic Products | 7 | 1 |
3.2 Diversification of Molecular Targets | 7 | 1 |
3.3 Innovative First-in-Class Product Development Remains Attractive | 7 | 1 |
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation | 8 | 1 |
3.5 Sustained Innovation | 8 | 1 |
3.6 GBI Research Report Guidance | 8 | 2 |
4 Clinical and Commercial Landscape | 10 | 12 |
4.1 Diabetes Mellitus Overview | 10 | 1 |
4.2 Diabetic Neuropathies | 11 | 1 |
4.2.1 Disease Overview | 11 | 1 |
4.2.2 Signs and Symptoms | 11 | 1 |
4.2.3 Epidemiology and Etiology | 12 | 1 |
4.2.4 Pathophysiology | 12 | 1 |
4.2.4.1 Oxidative Stress | 12 | 1 |
4.2.4.2 Polyol Pathway | 12 | 1 |
4.2.4.3 Advanced Glycation End Products | 12 | 1 |
4.2.5 Diagnosis and Staging | 12 | 1 |
4.2.6 Prognosis | 13 | 1 |
4.2.7 Treatment Options | 13 | 1 |
4.3 Diabetic Nephropathy | 14 | 1 |
4.3.1 Disease Overview | 14 | 1 |
4.3.2 Sign and Symptoms | 14 | 1 |
4.3.3 Epidemiology and Etiology | 14 | 1 |
4.3.4 Pathophysiology | 14 | 1 |
4.3.5 Diagnosis and Staging | 14 | 1 |
4.3.6 Prognosis | 15 | 1 |
4.3.7 Treatment Options | 15 | 1 |
4.4 Diabetic Retinopathies | 16 | 1 |
4.4.1 Disease Overview | 16 | 1 |
4.4.2 Signs and Symptoms | 16 | 1 |
4.4.3 Epidemiology and Etiology | 16 | 1 |
4.4.4 Pathophysiology | 16 | 1 |
4.4.5 Diagnosis and Staging | 17 | 1 |
4.4.6 Prognosis | 17 | 1 |
4.4.7 Treatment Options | 17 | 1 |
4.5 Overview of Marketed Products in Diabetic Complications | 18 | 1 |
4.5.1 Overview of Marketed Products in Diabetic Neuropathies | 18 | 1 |
4.5.1.1 Molecule Type and Target Analysis | 18 | 2 |
4.5.1.2 Unmet Needs | 20 | 1 |
4.5.2 Overview of Marketed Products in Diabetic Nephropathy | 20 | 1 |
4.5.2.1 Molecule Type and Target Analysis | 20 | 1 |
4.5.2.2 Unmet Needs | 20 | 1 |
4.5.3 Overview of Marketed Products in Diabetic Retinopathies | 20 | 1 |
4.5.3.1 Molecule Type and Target Analysis | 21 | 1 |
4.5.3.2 Unmet Needs | 21 | 1 |
5 Assessment of Pipeline Product Innovation | 22 | 19 |
5.1 Diabetic Neuropathies by Molecule Type, Phase and Therapeutic Target | 22 | 2 |
5.1.1 Comparative Distribution of Programs between Diabetic Neuropathy Market and Pipeline by Therapeutic Target Family | 24 | 1 |
5.1.2 First-in-Class Pipeline Programs Targeting Novel Molecular Targets | 25 | 2 |
5.2 Diabetic Nephropathy by Molecule Type, Phase and Therapeutic Target | 27 | 2 |
5.2.1 Comparative Distribution of Programs between the Diabetic Nephropathy Market and Pipeline by Therapeutic Target Family | 29 | 1 |
5.2.2 First-in-Class Pipeline Programs Targeting Novel Molecular Targets | 30 | 2 |
5.3 Diabetic Retinopathies by Molecule Type, Phase and Therapeutic Target | 32 | 2 |
5.3.1 Comparative Distribution of Programs between the Diabetic Retinopathy Market and Pipeline by Therapeutic Target Family | 34 | 1 |
5.3.2 First-in-Class Pipeline Programs Targeting Novel Molecular Targets | 35 | 3 |
5.3.3 Pipeline Products in Diabetic Complications | 38 | 3 |
6 Signaling Network, Disease Causation and Innovation Alignment | 41 | 3 |
6.1 Complexity of Signaling Networks in Metabolic Disorders | 41 | 1 |
6.2 First-in-Class Matrix Assessment | 42 | 2 |
7 First-in-Class Target Evaluation | 44 | 10 |
7.1 Pipeline Programs Targeting NADPH Oxidase 4 | 44 | 1 |
7.2 Pipeline Programs Targeting Glutamate Decarboxylase | 45 | 1 |
7.3 Pipeline Programs Targeting Growth Hormone Secretagogue Receptor Type 1 | 46 | 1 |
7.4 Pipeline Programs Targeting Motilin Receptor | 47 | 1 |
7.5 Pipeline Programs Targeting Lysophosphatidic Acid Receptor 1 | 48 | 2 |
7.6 Pipeline Programs Targeting Leukotriene B4 Receptor 1 | 50 | 1 |
7.7 Pipeline Programs Targeting Integrin Alpha V | 51 | 2 |
7.8 Pipeline Programs Targeting Signal Transducer and Activator of Transcription 4 | 53 | 1 |
8 Deals and Strategic Consolidations | 54 | 12 |
8.1 Industry-Wide First-in-Class Deals | 54 | 1 |
8.2 Licensing Deals | 55 | 2 |
8.2.1 Licensing Deals by Molecule Type | 57 | 1 |
8.2.2 Licensing Deals by Molecular Target | 57 | 2 |
8.3 Co-development Deals | 59 | 1 |
8.3.1 Co-development Deals by Molecule Type | 60 | 1 |
8.3.2 Co-development Deals by Molecular Target | 60 | 2 |
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals | 62 | 4 |
9 Appendix | 66 | 8 |
9.1 References | 66 | 5 |
9.2 Abbreviations | 71 | 1 |
9.3 Research Methodology | 71 | 1 |
9.4 Secondary Research | 72 | 2 |
9.4.1 Market Analysis | 72 | 1 |
9.4.2 Pipeline Analysis | 72 | 1 |
9.4.2.1 Overall Pipeline | 72 | 1 |
9.4.2.2 First-in-Class Analysis | 72 | 1 |
9.4.3 First-in-Class Matrix Assessment | 72 | 1 |
9.4.4 First-in-Class Target Profiles | 73 | 1 |
9.4.5 Licensing and Co-Development Deals | 73 | 1 |
9.5 Contact Us | 73 | 1 |
9.6 Disclaimer | 73 | 1 |